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ABSTRACT 
Premeditated Enzyme Inactivation: 
The Development of Mechanism-Based Irreversible Inhibitors 
of Glyoxalase I as Potential Anti-Cancer Agents 
Stuart Neal Isaacs 
1985 
The development of a mechanism-based irreversible inhibitor of an 
enzyme is the ultimate proof that a postulated enzymatic mechanism is 
operative. Halogenated methylphenylglyoxals (XV) were synthesized based on 
the theory that glyoxalase I proceeds via an enediol intermediate. The 
newly synthesized compounds could divert the enediol intermediate to a 
highly reactive species which would then covalently modify the enzyme and 
inactivate it- The in vitro findings of halogen ion release and the 
demonstration of irreversible enzyme inhibition by p- 
bromomethylphenyiglyoxal provides strong support for the premise that 
glyoxalase I acts via an enediol intermediate. While p- 
fluoromethylphenylglyoxal resulted in no enzyme inhibition, the enzyme 
inhibition by p-bromomethylphenylglyoxal might represent the first 
mechanism-based inhibitor of glyoxalase I. 
Based on the theory that the glyoxalase enzyme system constitutes a 
fundamental regulatory mechanism of cell growth and division the 
halomethylphenylglyoxals were tested as anti-cancer agents in tissue 
culture and in tumor-bearing mice. Significant cytotoxic effects of 
fluoro- and bromomethylphenylglyoxal against L1210 and P388 cell lines were 
observed. In tumor-bearing mice p-bromomethylphenylglyoxal revealed 
extreme toxicity, and early death to the mice. This is consistent with the 
potent effect of an irreversible enzyme inhibitor which causes the 
overwhelming accumulation of substances which inhibit cell growth and 
division. 
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INTRODUCTION 
It is ...difficult to exaggerate the importance 
to biology...of extended studies of enzymes and 
their action. 
— F.G. Hopkins (Presidential 
address to the Royal Society - 1932) (1) 
The glyoxalase enzyme system is now known to convert the 
thiohemiacetal (ID of an a-ketoaldehyde (D and glutathione (GSH) to the 
corresponding a-hydroxythioester (III) which is then hydrolyzed by 
glyoxalase II to the corresponding D-hydroxyacid Q3Z) and free GSH (Scheme 
I). Since its independent discovery in 1913 by Dakin & Dudley (2,3) and 
Scheme I: 
0 0 0 OH OH 0 
R-OU-C-CH + GSH ^ RCH9C-C-SG -g-LY- ■*■> RCH9C-C-SG 
z 2 i 1 H n\ 
1 II III 
GLY II 
RCH^-C-O" + GSH 
JY 
Neuberg (4), the glyoxalase system has been an area of considerable 
biological and mechanistic controversy. Although it has been found widely 
distributed (3,5) in animals, plants, and microorganisms, the actual 
physiological function of the system remains obscure to this day. There 
are many theories, most with tenuous evidence, of the definitive function 
of the glyoxalase system. 
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The theories serve to satisfy the mind, prepare 
it for 'an accident' and keep one going. I must 
admit that most of the new observations I made 
were based on wrong theories. My theories 
collapsed, but something was left afterward. 
-A. Szent-Gyorgyi (6) 
Probably the most controversial theory of the function of the 
glyoxalase enzyme system is that proposed by Albert Szent-Gyorgyi, the 1937 
Nobel Prize winner in Physiology and Medicine for his work on ascorbic acid 
and his studies of cellular respiration. Szent-Gyo*rgyi has proposed that 
methylglyoxal and the glyoxalase system constitute a fundamental regulatory 
mechanism of cell division and growth (7-10). His theory is based on his 
observations that a tissue extract, thought to be a ketoaldehyde (9), and 
later identified as methylglyoxal (11), reversibly inhibited cell growth 
(8). Szent-Gyorgyi, therefore, designated methylglyoxal as a retarder of 
division, the cell's internal "brake". The glyoxalase enzyme system is 
thought to be the promoter of division by the metabolism of methylglyoxal 
to D-lactate (10). A disturbance in this equilibria may be connected with 
a cause of cancer. Szent-GyBrgyi has extended this theory further into an 
even more controversial realm of "bioelectronics" (12-19). In this 
submolecular theory, he hypothesized that methylglyoxal is inherently 
important in maintaining the energy state of normal living matter, and that 
the energy state of living matter is altered in cancer. His studies using 
electron spin resonance have revealed that molecules of major biological 
importance, with low chemical reactivity, can give off a whole electron, 
thus forming a free radical. This suggests that charge transfer may be a 
common and fundamental biological reaction and he believes that the 
presence of methylglyoxal allows such a charge transfer. He calls 
methylglyoxal the "acceptor impurity of protein" whose action is to 
desaturate the otherwise electron filled ground state of proteins (15-18). 
"If there is a shortage of methylglyoxal or and excess of glyoxalase, there 
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is no charge transfer, and cells revert to the simple, non-stoppable 
proliferative state, which is cancer." (16) Therefore, according to 
Szent-Gyorgyi's theory, electronic desaturation of protein is a central 
event of cell life and a low level of desaturation is seen in cancer 
(14,17). 
Other researchers have tried to assign different functions to the 
glyoxalase system. Kun (19), who found that methylglyoxal inhibited 
succinic dehydrogenase and other similar enzymes suggested that the 
glyoxalase enzyme system eliminated spontaneously formed methylglyoxal to 
prevent the inactivation of enzymes containing sulfhydry 1-groups. Salem 
(20) supported this idea that spontaneously formed methylglyoxal was 
detoxified by glyoxalase and that the wide distribution of the enzyme in 
all types of tissues from species of all phyla is in keeping with a role of 
this kind. A Belgium group (21), gave strong evidence that in yeast, the 
glyoxalase pathway is a defense mechanism against methylglyoxal produced by 
the spontaneous decay of accumulating triose phosphates during glycerol 
catabolism. 
Recent studies by Gillespie (22-25) suggest that methylglyoxal and the 
glyoxalase enzyme system may be involved in the mediation of the immune and 
inflamatory responses. She has shown that the product of the glyoxalase I 
reaction, S-lactoylglutathione (III. RrCH-j; Scheme I), is a physiologically 
important species regulated by the glyoxalase system. Concanavalin A is 
known to increase centriole-associated microtubules in polymorphonuclear 
leukocytes (23). In vitro studies revealed that this assembly occurred in 
the same time frame of glyoxalase I activation, resulting in the buildup 
of S-lactoylglutatione. This thioester was also shown to be a potentiator 
of histamine release in human leukocytes (24). Her work with a phorbol 
ester, a known inflamatory agent and potent carcinogen, revealed that it 
caused elevated glyoxalase I activity and decreased glyoxalase II activity 
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in human leukocytes (25). This is compatible with the hypothesis that 
increased levels of S-lactoylglutathione are a concomitant of inflamation. 
It is also possible that the increased levels of this thioester is related 
to the tumor promoting properties of phorbol esters. This is all 
consistent with Szent-Gyorgyi's theory that cancer cells have increased 
glyoxalase activity which cause a decrease in endogenous methylglyoxal. 
Others doubted the existence of intracellular methylglyoxal and 
postulated that the glyoxalase system was involved in the reactions of 
other intracellular ketoaldehydes. Thus, some naturally occuring 
ketoaldehydes, phosphohydroxypyruvic aldehyde (26), hydroxypyruvic aldehyde 
(27), and y,S-dioxovalerate (28), were shown to be substrates of the 
glyoxalase enzyme system. 
The debate over the existence of methylglyoxal as a natural 
constituent of cells was finally concluded in 1970 when Cooper and co¬ 
workers (29-31) made the important discovery of the enzyme methylglyoxal 
synthase. This enzyme originally found in £*. coli. catalyzes the 
conversion of dihydroxyacetonephosphate (DHAP) to methylglyoxal and 
phosphate. Previous to this discovery, some thought that the methylglyoxal 
found in cells was formed non-enzymatically (32,33). Methylglyoxal 
synthase serves as a bypass of triose-phosphate isomerase. Methylglyoxal 
synthase, in conjunction with glyoxalase and D-lactate dehydrogenase, 
constitutes an alternative to the Embden-Meyerhof glycolysis pathway (29). 
(See Scheme II). This bypass does not result in ATP formation because it 
bypasses both substrate-linked phosphorylations of glycolysis. At first. 
Cooper (29) thought that it might play a role by preventing the 
accumulation of high concentrations of phosphorylated glycolytic 
intermediates which inhibit growth. Later, his data (30,31) suggested that 
the pathway would be important when glycolysis was restricted by reduced 
availability of inorganic phosphate (P^). With decreased P^, 
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Scheme II:(29) 
glucose 
l 
glucose-6-phosphate jr 
fructose-6^phosphate 
FRUCTOSE-1y6-DIPHOSPHATE 
DI HYDROXY ACETONE-PHOSPHATE ?=iGLYCERALDEHYDE-3-PHOSPHATE 
> I 
1,3-DIPHOSPHOGLYCERATE 
J[ 
3-PHOSPHOGLYCERATE 
Jf 
2-PHOSPHOGLYCERATE 
Jf 
PHOSPHOENOLPYRUVATE 
^ ) PYRUVATE-x 
METHYLGLYOXAL 
D-LACTATE 
glyceraldehyde-3-phosphate dehydrogenase would be inhibited and as a 
consequence the triose phosphate concentration would rise. The bypass 
scheme would then function by methylglyoxal synthase liberating P^, thus 
replenishing intracellular P^, and then glyoxalase would generate lactate 
which is an energy source under aerobic conditions. Methylglyoxal synthase 
was initially found in bacteria and has more recently been found in rat 
liver (34) and isolated from goat liver (35). Thus, the existence of an 
enzyme to make methylglyoxal suggests that this compound may indeed have a 
significant biological role. 
Even though Szent-Gyorgyi's theory that the glyoxalase system 
constitutes a fundamental regulatory mechanism for cell division and cell 
growth remains controversial, it has, none-the-less, stimulated much 
thought and research on the possible connections of this enzyme system and 
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cancer. Work which lends some support to Szent-Gyorgyi's theory are the 
studies of glyoxalase activity in cancerous tissues and tissues undergoing 
rapid growth; as well as studies of the keto-aldehyde's inhibitory effects 
on cell growth and division. Early studies (36) generally showed no 
evident differences between cancerous and normal animals in the glyoxalase 
content of corresponding organs. More recent studies by Norton and co¬ 
workers (37) have shown that for the first ten days after tumor implant, 
there is an increase in tissue glyoxalase enzyme activity versus tissues of 
normal animals. The increased glyoxalase activity during the early stages 
of tumor formation goes along with Szent-Gyorgyi's theory that glyoxalase, 
by metabolizing methylglyoxal, is a cell growth promoter. However, after 
ten days there is an overall decrease in glyoxalase activity in tumor¬ 
bearing mice, but this decreased activity paralleled the decreased activity 
seen in other enzymes studied in tumor bearing mice. Norton's group also 
showed that the glyoxalase I enzymes isolated from the liver of tumor¬ 
bearing mice and normal mice were different protein molecules, but, with 
the same pH optima and Km's. They concluded that the glyoxalase I isolated 
from tumor-bearing mice was modified due to the presence of tumor (38). 
Brandt (39) studied the possible changes in the glyoxalase system with 
rapid growth. He found that the final product of the glyoxalase reaction, 
D-lactate, was increased in the blood of rats at the end of their rapid 
growth phase. He concluded that if D-lactate concentration reflects 
cellular methylglyoxal levels, then the hypothesis that methylglyoxal is a 
natural growth inhibitor is supported because, as observed, its level would 
increase as the animals reach the end of their rapid growth phase. An 
Italian group (40) studied glyoxalase I and II activity in the regenerating 
rat liver. Rat liver regeneration peaks at 28 hours and then falls 
rapidly. They found significantly increased glyoxalase I activity at 24 to 
48 hours after partial hepatectomy. The high glyoxalase I activity during 
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the regeneration period support Szent-Gyorgyi's theory that glyoxalase I 
activity reduces the intracellular content of growth inhibitors. Increased 
glyoxalase II activity at 16, 48, and 72 hours with a transient decrease in 
activity at 24 hours, was correlated with an interval when proliferative 
activity is nearly stopped. Therefore, they proposed that it was the 
changes in concentration of the thioester, the intermediate compound 
between the glyoxalase I and glyoxalase II reaction, that is also important 
in growth regulation. That is, a decrease in this substance, by increased 
glyoxalase II activity, causes cellular proliferation to be shut down. In 
support of this, a Polish group (41) found that glyoxalase II activity was 
absent in cancerous tissues and cells. They claimed that this is a 
characteristic feature that distinguishes cancerous tissues from normal 
tissues. Thus, they agree with Szent-Gydrgyi that a fundamental factor in 
the cancer process is a disruption in the glyoxalase enzyme system. 
The effects of ketoaldehydes on growth and division have been known 
for a long time. They have been tested as viricidal agents (42-46), and 
are known inhibitors of bacterial and cellular growth and division (8,47— 
50). Egyiid & Szent-Gydrgyi (8) found that low levels of methylglyoxal 
inhibited cell division of coli. fertilized sea urchin eggs, 
flagellates and cells in tissue culture. Methylglyoxal has also been found 
to inhibit adult kidney cell growth (50). Ketoaldehydes have also been 
extensively studied as possible carcinostatic agents (51-55), and, in fact, 
the ketoaldehyde, 3-ethoxy-2-ketobutyraldehyde (Kethoxal ) was at one time 
marketed as a carcinostatic drug. In experimental set-ups, the glyoxal 
compounds have been found to be most active against mice ascites carcinoma, 
mammary carcinoma, leukemia, adenocarcinoma, lymphosarcoma, and sarcoma 
(53,54). Egyiid & Szent-Gydrgyi (54) noted that cancer cells in tissue 
culture were more sensitive to the inhibitory effects of methylglyoxal than 
normal cells in culture. However, the chemotherapeutic value of »- 
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ketoaldehydes are limited by their rapid metabolism by the glyoxalase 
system. 
The observations of the potent inhibitory effects of the ketoaldehydes 
led to the studies of how this inhibition occurred. Early on, Egyiid & 
Szent-Gyorgyi (8) showed that the inhibition was not due to the cessation 
of oxidative metabolism. Their biological studies on E. coli (56) using 
radioactive compounds revealed that methylglyoxal inhibited protein 
synthesis and to a lesser degree, DNA and RNA synthesis. This has been 
confirmed (57,58) and similar results have been obtained using malignant 
ascites cells (59), mouse lymphoma cells (49), and cultured guinea pig 
keratocytes (GFK) (60). The effect of the inhibition is to stop cells from 
continuing through their life cycle, regardless of where the cell is in the 
cell cycle when the ketoaldehyde is added. One study on coli (58) 
showed that methylglyoxal, by interfering with protein synthesis, inhibited 
DNA synthesis by interacting with an initiation complex. They also found 
that methylglyoxal disrupted cell division by preventing the synthesis of a 
termination protein required for cell division. Another study on GPK cells 
(60) showed that methylglyoxal directly inhibited protein and RNA synthesis 
individually. The inhibition of protein synthesis resulted from an 
inhibition of the initiation of translation. RNA synthesis was inhibited 
by a block in the maturation of the 32S rRNA precursor. Methylglyoxal has 
also been shown to react with the 7-methylguanosine cap structure of 
eukaryotic mRNA to cause an inhibition of protein synthesis (61). 
Recently, Riley (62) determined that a methylglyoxal-ascorbate adduct (NFCR 
278021) isolated by Fodar, effectively inhibited protein synthesis. The 
inhibitory effect of the adduct on protein synthesis was found to be 
decreased in the presence of GSH and glyoxalase. 
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To [attempt] cure.. .without understanding it is 
similar to trying to repair a machine without 
knowing hew it works. 
-A. Szent-Gyorgyi (63) 
Throughout the years of controversy of the biological role of the 
glyoxalase enzyme system, a detailed understanding of the catalytic 
mechanism was accumulated. The first theory of the mechanism by which 
glyoxalase functions was put forward by Dakin & Dudley (3) who observed 
that the reaction was similar to the in vitro reaction of ketoaldehydes in 
alkaline solution (i.e. what is now called a Cannizarro Reaction). Lohmann 
(64) discovered that the tripeptide, -glutamylcysteineglycine or 
"glutathione" (GSH) was a coenzyme of glyoxalase. Jowett & Quastel (65) 
proposed the formation of a condensation product between methylglyoxal and 
glutathione (GSH) as an intermediate to lactic acid production. Yamazoye 
(66) was first to show the presence of an intermediate distinct from the 
addition complex between methylglyoxal and GSH in crude tissue extracts. It 
was not until 1950 when Hopkins & Morgan's (67) "factor" which accelerated 
the glyoxalase reaction was identified by Racker (68,69) and Crook & Law 
(70,71) as another enzyme which was present in the original crude 
glyoxalase preparations. Thus, two individual enzymes, glyoxalase I and 
II, were firmly identified. Of equal importance, Racker introduced a 
spectophotometric method of following the glyoxalase reactions, thus 
replacing the cumbersome manometric techniqes used in the past. Both 
groups also determined a difference between the chemical condensation 
product and Yamazoye's biological product. The chemical intermediate 
(proposed as XL, Scheme III) was unstable in acid and alkali, decomposing 
to methylglyoxal and GSH. The biological product (proposed as Ilia. Scheme 
III) formed by the action of glyoxalase I was stable on the acid side of 
neutrality and decomposed to lactic acid and GSH on the alkaline side of 

11 
neutrality. Both groups proposed reaction pathways similar to Scheme III. 
Scheme III:(adapted fran 70) 
0 OH 
RCI^C-C-SG (labile) 
II 
0 0 
RCH2C-CH + GSH 
I 
(stable 
canpound) 
■ 0 0 ' 
rch2c-ch 
. GSH 
Ilia 
OH 0 
GLY -U> RCHoC—C-0~ + GSH 
^H 
IV 
At that time. Crook & Law (71) also noted the low specificity of the 
enzymes for the glyoxal substrate but the very high specificity of 
glyoxalase for the GSH coenzyme. In 1961, Cliffe & Waley (72) gave 
evidence that the thiohemiacetal adduct II was the substrate for glyoxalase 
I. This was shown in a reaction at high glyoxalase I concentration and low 
methylglyoxal and GSH levels. The rate of the reaction was revealed to be 
determined by the non-enzymatic formation of the thiohemiacetal (II). This 
was confirmed by Davis & Williams (73) who concluded that glyoxalase I acts 
as an oxidoreductive isomerase. Thus, Scheme I is the accepted pathway of 
the glyoxalase enzyme system. Further confirmation of a one substrate 
pathway have been offered by Vander Jagt (74) and Marmstal & Mannervik 
(75). It is known that the product of glyoxalase I reaction is 
stereospecific and an initial study (76) using high-resolution 1H-NMR 
revealed that glyoxalase I selected the proper thiohemiacetal diastereomer 
for processing. The investigators concluded that the most likely origin of 
the product stereochemistry was a selective binding site on glyoxalase I 
for the proper diastereomer. However, this was not confirmed by Creighton 
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(77) who found through a series of isotope-trapping experiments that 
glyoxalase I operated on the mixture of thiohemiacetal diastereomers. 
Chari & Kozarich (78) have recently deduced the absolute stereochemical 
course of glyoxalase I. Their work supported the finding of a single 
stereochemical outcome of the two thiohemiacetal isomers when processed by 
glyoxalase I. However, this most likely occurred by an epimerization of 
the wrong isomer prior to the stereospecific proton abstraction by 
glyoxalase I which results in a single stereospecific product. 
As stated previously (71,74,79), glyoxalase I was found to have a 
broad specificity for both aliphatic and aromatic a-ketoaldehydes 
(reflected by nearly identical Vmax). However, the Vmax dropped abruptly 
if the side chain of the a -ketoaldehyde was sterically crowded or polar 
in nature. Thus, the active site has a non-polar region and has a space 
constraint. Mannervik (80,81) has shown that sulfhydryl groups on the 
enzyme are not involved in glyoxalase's catalytic activity and that a 
tryptophan near the active site is involved in the binding of the 
substrate. Reed (82) using a similar experimental technique found an 
arginine residue near the active site that is involved in substrate binding 
via the GSH. 
A metal ion at the active site was suggested by Davis & Williams (83) 
when they found that during purification a metal-chelator totally 
inactivated the enzyme. The activity was restored most effectively when 
Mg++ ions were added. They theorized that the divalent cation played a 
direct part in the catalysis of the thioester formation. Later, Mannervik 
and co-workers (84) found that it was actually Zn that was tightly bound 
to glyoxalase I. They felt that the metal ion acted in the catalytic 
reaction or that it functioned to maintain the enzyme structure. Later 
work (85,86) by this group proved that the zinc ion was at the active site 
of the glyoxalase I enzyme. 
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The mechanism of glyoxalase I has been an area of as much controversy 
as that centered on the biological role of the glyoxalase enzyme system. 
Racker (69) proposed that the mechanism of glyoxalase I was through an 
enediol intermediate (Va. See Scheme IVa) which would proceed via a proton 
Scheme IV: 
0 0 
(0 OH 
RCH2-C^C-SG 
H 
*-;B-ENZ 
IW 
W 
RCHo-C-C-SG 
2*® 
II 
' W " 
RCH2C=tC-SG 
Hb-Enz 
© 
Va 
GLY I 
OH 0 
RCHoC—C-SG 
ZH 
III 
transfer. However, when Rose (87) ran the glyoxalase I reaction in 
tritiated water, he failed to observe the incorporation of tritium into the 
product and this contradicted the possibility of an enediol intermediate. 
Because the conversion of methylglyoxal to lactic acid resembled the 
Cannizzaro reaction, (an alkaline catalyzed reaction known to convert 
methylglyoxal to lactic acid by a direct 1,2-hydride shift) he proposed 
that the glyoxalase I reaction was analogous to the Cannizzaro reaction and 
therefore the mechanism was a direct 1,2-hydride shift (See Scheme IVb). 
These results were confirmed when Franzen (88) failed to detect the 
incorporation of deuterium in the product of the glyoxalase I reaction 
run in deuterated solvent. 
Davis & Williams (83) supported a hydride shift mechanism which would 
proceed via a cyclic transition state of the thiohemiacetal (IX) and the 
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newly discovered metal cation. Such a mechanism was a variation of the 
Meerwein-Ponndorf-Oppenauer reaction. Vander Jagt (79,89,90) favored the 
1,2-hydride shift mechanism of glyoxalase I, however, some of his results 
made him question this conclusion. For instance, in his work on the broad 
specificity of glyoxalase I for a-ketoaldehydes, he found no substituent 
effect of the substituted a -ketoaldehydes on the rate of the reaction 
(79). If the mechanism was a hydride shift, one would expect to see a 
substituent effect depending on the polarity of the a-ketone carbonyl 
(due to the transition state stabilization by electron withdrawing groups). 
This substituent effect existed in the alkaline catalyzed Cannizzaro 
reaction (89). He felt that the above observations suggested that either 
the hydride shift was not the rate determining step or that the hydride 
migration was facilitated through the polarization of the <* -ketone group 
ty the enzyme. In the latter case the effects of substituents may be small 
and the hydride shift could still be rate determining (79). However, 
experiments (90) measuring deuterium isotope effects revealed that the 
hydride shift was rate determining, and he therefore concluded that the 
side chains of substituted a -ketoaldehydes do not make a significant 
contribution to the polarity of the a -ketone group because the enzyme 
polarizes the a-ketone group in some way. 
Hall (91) studied the rearrangement of a -ketoaldehydes (D and thiols 
to a -hydroxyesters (ill) in the presence of a "general base" (e.g. a 
tertiary amine) and deuterated solvent and found deuterium incorporation in 
the -hydroxyester. But it was not until 1976 when Hall, et al. (92) 
detected the incorporation of solvent protons into the product of the 
glyoxalase I reaction. The percentage of incorporation increased with 
temperature. His group proposed a mechanism whereby a fast proton transfer 
via an enediol was taking place in a highly protected active site. 
Experiments measuring deuterium isotope effects (93) indicated that the 

15 
hydrogen transfer was rate limiting, but did not distinguish the nature of 
the hydrogen transfer. Another group (94) provided further evidence for a 
proton transfer mechanism when they detected the slow exchange of the 
hydroxymethylene proton of the product, S-CD-lactqyl)glutathione (III) with 
solvent. 
A problem with solvent incorporation as a means of determining the 
reaction mechanism is the possibility of proton exchange occurring by a 
fortuitous side reaction after the catalytic step and prior to product 
release. This had led researchers to continue to investigate the reaction 
mechanism of glyoxalase I. Shinkai (95) using a "flavin-trapping" 
technique provided evidence that the chemical reaction occurred via an 
enediol intermediate. Complete reaction inhibition was seen in a test 
model system of the general base catalyzed rearrangement of thiohemiacetals 
to the corresponding a-ketoacids in the presence of a flavin compound. 
Flavin compounds react with transient carbanion intermediates, but do not 
serve as efficient hydride acceptors. 
Recently, Kozarich (96-98) designed experiments which definitively 
proved the glyoxalase I mechanism to be that of a proton transfer. The 
design (98) centered around the expected differences in the charge 
densities on the C-2 position of the ketoaldehyde. In the enediol 
mechanism (Scheme iva) one would expect the buildup of carbanionic 
character at this carbon in order to enhance proton transfer from the 
active site base. In the hydride shift pathway (Scheme IVb) one would 
expect an increase in carbonium ion character at this carbon in order to 
facilitate the transfer of the hydride from the C-l position of the 
thiohemiacetal. With the proper substrate, one could distinguish between 
the two mechanisms. The group synthesized halomethylglyoxals Qa) which 
would be sensitive to the charge density on the C-2 carbon. Thus, if the 
enediol mechanism was correct one would expect the possibility of halide 
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elimination (Scheme V). However, one would expect no halide elimination if 
Scheme V: (adapted from 96) 
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the hydride transfer mechanism was operating. And, in fact, under typical 
Cannizzaro reaction conditions, no halogen was released. The above 
experimental design eliminated the possible ambiquity of solvent 
incorporation. 
Fluoromethylglyoxal (VI? X=F) was studied (96) and the results were 
consistent with a rapid proton-transfer mechanism. As hypothesized, the 
enzymatic reaction with glyoxalase I yielded total fluoride release which 
could best be accounted for by a carbanionic character at C-2. If the 

17 
same reaction was performed in the presence of both glyoxalase I and II, 
then three products were obtained (See Scheme V). F-NMR determined that 
the only fluorine containing products were fluorolactate and fluoride. The 
other product was pyruvate (determined to be present enzymatically). The 
above results could best be accounted for by Scheme V, which shows the 
unique glyoxalase I catalyzed partitioning of the enediol intermediate 
between protonation to yield S-fluorolactqylglutathione CXa, path a) and 
elimination of fluoride to first form an enol (IXb. path b) which then 
tautomerizes to form S-pyruvylglutathione (Xb. path b). Hydrolysis of the 
thioesters by glyoxalase II yields the products fluorolactate (path a) and 
pyruvate (path b) which undergo no further reactions. This example of 
product partitioning provided strong support for the proton transfer 
mechanism. 
However, the results outlined above could also be accounted for by a 
fortuitous side reaction by an active site base after the catalytic step. 
Thus, the possibility of a 1,2-hydride shift was not ruled out. The 
definitive proof of the enediol intermediate of the glyoxalase I reaction 
was shown by isotope effects on the product partitioning of 
fluoromethylglyoxal-d^, (97). Isotope effects in the past (90,93) were 
unable to distinguish between the two possible mechanisms. The difference 
in Kozarich's design was that an isotope effect on the unique partitioning 
of products of the glyoxalase system reaction would allow one to 
distinguish between proton transfer and hydride shift with 6-elimination. 
Since the observed partitioning measures the competition of two kinetic 
processes (i.e. fluoride elimination versus protonation) the selective 
disruption of one of these rates would have resulted in a change in the 
observed partitioning. If the enediol mechanism was correct (Scheme VI), 
abstraction of the deuterium from C-l by the active base would result in 
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the formation of the enediol and deuterated base. Now a primary isotope 
effect on the reprotonation of the enediol at C-2 would result in a delay 
in the formation of fluorolactoylglutathione and the overall effect would 
have been to increase fluoride elimination (kD is selectively decreased by 
the isotope effect on the dueterated base, Scheme VI). The opposite result 
was expected if the hydride shift mechanism was operative. A 1,2-deuteride 
shift from the thiohemiacetal would have yielded deuterated 
fluorolactoylglutathione directly (Scheme VII). The primary isotope effect 
Scheme VII:(97) 
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would result in a decrease in the rate of elimination and the overall 
effect would have been to decrease fluoride elimination (kg^ is selectively 
decreased by the isotope effect on deuterated C-2, Scheme VII). Chari & 
Kozarich's results (97) clearly demonstrated an increase in the amount of 
fluoride released when the deuterated substrate was compared to the non- 
deuterated compound. This finding was only consistent with a primary 
isotope effect on the partitioning reaction involving a proton transfer to 
an enediol intermediate. Thus, this established a compelling argument for 
the proton transfer mechanism of glyoxalase I first proposed over thirty 
years ago (69). 
During Kozarich & Chari’s studies with halomethylglyoxals, they 
discovered a unique example of "inverse" substrate processing by glyoxalase 
I. This work (99) has re-emphasized the need for glutathione for substrate 
binding, as well as the requirement of thiohemiacetal formation for 
catalysis. It also gives further information about the "size" of the 
enzymatic active site, which in the past (74) was found to have a poor fit 
with sterically hindered side chains of substituted a-ketoaldehydes. 
Scheme VIII depicts the method by which Kozarich & Chari were able to 
form B-(alkylthio)-a -ketoaldehydes Oil) and specifically the glutathione 
adduct (XI. R=GSH). When B- (glutathiomethyl) glyoxal was processed through 
Scheme VIII, pathway a, the majority of product formed was L-lactate. 
Ifaus, one observed a total reversal of the expected stereochemistry of the 
glyoxalase enzyme. The investigators, therefore, proposed that the 
substrate binds to the active site in an inverted manner allowing the 
stereochemistry to be reversed. They termed this process "mirror-image" 
catalysis and proposed Figure 1 as a possible explanation. Figure 1A 
depicts normal binding in which glyoxalase processing would form the D- 
isomer. Figure 2B illustrates the inverted binding of the "inverse" 
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Figure 1:(99) 
substrate which due to the constraints of the system necessitates the 
opposite processing resulting in the L-isomer. 
Glyoxalase I [S-lactoylglutathione methylglyoxal-lyase (isomerizing) 
EC 4.4.1.5] has been isolated in high purity from a number of different 
sources ranging from yeast (90), mouse liver (38,100,101), sheep liver 
(102), and various tissues from rat (103). The molecular weight of the 
mammalian enzyme has been found to be between 45,000-52,000. In contrast 
to the yeast enzyme, Oray & Norton (100) were the first to discover that 
mammalian glyoxalase I consisted of two identical subunits. It appears 
that each subunit has an active site (80,81). Vander Jagt (103) showed 
that within a species there is only a single form of the enzyme. However, 
between species, the activities, properties and amino acid composition of 
glyoxalase I vary (104). This has been supported by Chari & Kozarich (97) 
who found different partitioning ratios of products depending on the origin 
of enzyme used. 
Glyoxalase II [S-2-Hydroxyacylglutathione hydrolase, EC 3J.2.6) which 
catalyzes the hydrolysis of the thioester to the corresponding 
a-hydroxyacid has also been highly purified. Like glyoxalase I it is 
highly specific for GSH, but unspecific for the acylgroup of the thioester 
(105). Its molecular weight is about 30,000 (106) and its activity is 
normally less than than of glyoxalase I (107). 
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...I believe...[methylglyoxal] is the universal 
brake of proliferation...and glyoxalase is its 
switch. 
-A. Szent-Gyorgyi (14) 
Because one of the major roles suggested for the glyoxalase enzyme 
system is that of regulation of cell growth and division, the possibility 
exists that cancer cells have lost their ability to maintain a proper 
balance of methylglyoxal. Attempts have been made to try and influence the 
complex equilibria between methylglyoxal, glyoxalase, and lactic acid. 
a-Ketoaldehydes are known growth inhibitors. The problems of achieving 
suitable doses of methylglyoxal or other reactive ketoaldehydes for 
systemic control of cell growth and division are due to their inherent 
toxicities, as well as the widely distributed glyoxalase system which 
causes their inactivation. Another approach to disturb the regulatory 
system has been the development of inhibitors of glyoxalase I, the enzyme 
which converts a -ketoaldehydes and glutathione to thiohemiacetals. In 
the past, this enzyme has been shown to have increased activity in 
cancerous and regenerating tissues. Therefore, by inhibiting this enzyme 
one could possibly disrupt growth by allowing the intracellular buildup of 
growth inhibiting substances. Another goal in the development of enzyme 
inhibitors is their usefulness as probes in elucidating the mechanism and 
possible biological significance of an enzyme system. 
Research first centered around the design of competitive inhibitors of 
glyoxalase I. Kermack & Matheson (108) found that various analogues of 
GSH, the most active having a large alkyl group substitution, to be pure 
competitive inhibitors of glyoxalase I. Similar inhibitors were developed 
by Vince and co-workers (109,110) whose compound, S-p- 
bromobenzylglutathione, is presently the best reversible inhibitor known, 
with 50% enzyme inhibition of 0.009 mM. They found these compounds to 
be cytotoxic versus L1210 leukemia and KB cells in tissue culture. Vince 
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(110) stated that by increasing the intracellular methylglyoxal, one 
inhibited protein synthesis. Protein inhibition occurred by methylglyoxal 
binding to RNA guanine residues. This adduct was stable at acid pH (111) 
and therefore Vince hypothesized that one might be able to have selectivity 
in methylglyoxal's effect on cancer versus normal tissue. Norton (112), 
using the fact that S-substituted glutathiones strongly interacted with 
glyoxalase I, developed S-substituted glutathiones for the use as ligands 
for the affinity chromatography purification of glyoxalase I. 
Vince (113,114), noted that the S-substituted competitive inhibitors 
were rapidly metabolized In vivo by glutathionase, rendering the inhibitors 
inactive. He then developed glyoxalase I inhibitors which could resist 
degradation. However, these S- and N- substituted cysteinylglycines 
exhibited non-competitive inhibition of glyoxalase I and Vince therefore 
concluded that they were binding to a site other than the active site. 
Recently (115) esters of several glutathione analogues were synthesized in 
which the glycine was replaced by a straight-chain fatty acid and the 
mercapto group was benzylated. This type of compound, which inhibited 
glyoxalase I, was not hydrolyzed by glutathionase or cysteinylglycinase and 
has high lipohilicity. However, they did not inhibit P388 lymphocytic 
leukemia in mice. 
Hall (116) synthesized a-hydroxythiol esters and found them to be 
competitive inhibitors of glyoxalase I. However, when tested against L1210 
leukemia cells, he found no antitumor activity and thought this might be 
due to the ease of hydrolysis of the compound In vivo. 
Oray & Norton (117) found that both glyoxalase I and II from different 
tissues were equally inhibited by nucleotides and nucleosides in an 
apparently cooperative manner. They raised the point that intracellular 
levels of the tested nucleotides are at concentrations higher than what was 
needed to inhibit both enzymes. The physiological significance of this has 
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not been shown. Another interesting competitive inhibitor of glyoxalase I 
was studied by Douglas (118). He showed that yeast glyoxalase I was 
inhibited by porphyrin derivatives, possibly by active site occlusion. As 
referred to earlier (28), y , 6 -dioxovalerate, the transamination product 
of the first committed intermediate of porphyrin biosynthesis, is a known 
substrate of glyoxalase I. This possible complex interrelationship of 
glyoxalase with the heme biosynthetic pathway has not been worked out. 
From the above data, it appears that some competitive inhibitors are 
excellent glyoxalase I inhibitors in vitro. However, mostly because of 
their own metabolism and inactivation, competitive inhibitors are not 
likely to be useful inhibitors of glyoxalase I in vivo. Therefore, 
attention turned to the development of mechanism-based, transition-state 
(119) inhibitors where tighter binding of the transition state analog 
occurs. The mechanism of glyoxalase I is known to proceed through an 
enediol intermediate. Therefore, Douglas & Nadvi (120) synthesized 
compounds designed on transition state analogy. The compounds all 
resembled the enediol intermediate, (See Figure 2) and showed excellent 
Figure 2:(U9) 
if 
HO H0'\} 
a. b. 
inhibition, but had inhibition constants no better than the competitive 
inhibitor p-bromobenzylglutathione and are therefore excluded as tansition 
state analogs. Similarly, Brandt, et al. (121) selected compounds to test 
on their similarity to the enediol intermediate of the glyoxalase I 
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reaction. They found that some derivatives of couraarin (See Figure 2d) to 
be the most effective inhibitors of this type with a of 0.03 mM. But 
this still is not as good as inhibition by p-bromobenzylglutathione. 
Therefore, no effective transition state based inhibitor has been found for 
glyoxalase I. 
Suicide inactivators...depend upon the specific 
catalytic capabilities of the active site. 
-Abeles & Maycock (122) 
The main goal of my project was to synthesize a potential mechanism- 
based, suicide inhibitor of glyoxalase I. Kozarich and co-workers (96) 
were aware of the possibility that their halomethylglyoxals could function 
as mechanism-based inhibitors of glyoxalase I. They proposed a mechanism 
(see Scheme IX) whereby the transient enol (ixb) of S-pyruvylglutathione 
Scheme IX: 
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generated by halide elimination, might be susceptible to Michael addition 
by an active site nucleophile. This would result in covalent modification 
and inactivation of the enzyme (XIV). Kuo, et al. (123) have shown that 
the enol of pyruvate is sufficiently long lived for Kozarich's proposed 
Michael addition to occur. However, no inactivation was detected (96). 
Trapping experiments (98) suggested the presence of (IXb) in solution. 
Therefore, inactivation might not have been seen because an active site 
base was not accessible to the enol (IXb) for attack, or that IXb was not 
sufficiently active to undergo Michael addition. In order to take 
advantage of the enediol intermediate, p-halomethylphenylglyoxals were 
synthesized. These compounds could divert the enediol to a highly reactive 
species which could covalently modify glyoxalase I and inactivate it (See 
Scheme X). When the thiohemiacetal of XV and GSH react with glyoxalase I, 
the corresponding enediol (xvil) is generated. The intermediate could 
follow path a. Scheme X, and undergo fast-shielded protonation to yield the 
thioester (XVIII). Or the enediol could follow path b. Scheme X, and 
eliminate the halogen to generate the very reactive quinoid-like structure 
XIX which is an electron deficient species, xix would then be highly 
susceptible to Michael addition by an active nucleophile which could attack 
it and form a covalently modified enzyme, XX. Thus, the 
halomethylphenylglyoxals are potential mechanism-based inhibitors of the 
glyoxalase enzyme system and therefore might ultimately prove to be useful 
antineoplastic agents, as well as be useful in further elucidating the 
physiological role of the glyoxalase enzyme system. 
The compounds I prepared, p-bromo- and p-fluoromethylphenylglyoxal 
had previously never been synthesized. They were studied with glyoxalase I 
In vitro using standard enzymatic techniques. Some of the products of the 
enzymatic reactions were identified by NMR analysis. The reaction 
mechanism of an intermediate enediol was studied by employing techniques of 
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specific ion electrode analysis. Inhibition of glyoxalase I was 
investigated using standard techniques of kinetic analysis. The compounds 
were also tested in cell culture against L1210 and P388 cell lines as an 
initial screen for antitumor activity. Finally, the halogenated 
methylphenylglyoxal's anti-cancer activity were tested in vivo in tumor¬ 
bearing mice. 
The newly synthesized halomethylphenylglyoxals were also used to form 
p-glutathiomethylphenylglyoxal (XXIV) which was then studied as both a 
substrate and a potential inverse substrate of glyoxalase I. 
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MATERIALS AND METHODS 
A. SYNTHETIC METHODS 
Starting materials were of analytical grade from either Aldrich or 
Fisher Scientific, unless otherwise noted. Solvents were distilled and 
stored over molecular sieves. Melting points were determined on a Thomas- 
Hoover capillary melting point apparatus and are uncorrected. ^H-NMR 
spectra were routinely recorded in the noted solvent on a Varian T-60A 
Analytical NMR Spectrometer. The chemical shifts are expressed in 6 values 
(parts per million) relative to Me4Si internal standard. Microanalyses 
were performed by Atlantic Microlab, Inc., Atlanta. Analyses are indicated 
by symbols of the elements and represent analytical values which were 
within ± OJ. % of theoretical values. Ultraviolet spectra were determined 
in a potassium phosphate buffer with a Beckman Model 35 Spectrophotometer. 
Mass spectra data was obtained on a Hewlett-Packard 5985 GC Mass 
Spectrometer. 
Purification O-f N-bromosuccinimide (NBS) — Following a literature 
procedure (124), NBS (25g) was added to boiling distilled water (250 ml) 
and swirled for about two minutes until all the crystals were dissolved. 
The resulting yellow solution was poured through a fluted filter into a 
flask immersed in an ice-water bath and allowed to stand in the ice bath 
for two hours. The resulting mixture was then filtered through a Buchner 
funnel with suction. The white crystals were washed with two portions of 
ice-cold water (50ml) and then dried first under water vacuum and then in a 
lyophilyzer for 24 hrs. Yield: 58%. 
Synthesis oL p-bromomethvlacetophenone — Following a previously reported 
procedure (125), NBS (14.0 grams; 0.079 moles), benzoylperoxide (10 mg). 
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and p-methylacetophenone (10.6 g; 0.079 moles) were mixed in carbon 
tetrachloride (90 ml). This solution was held at reflux and irradiated 
with a 275-W sun lamp for about one hour (until the originally floating NBS 
appeared to be converted entirely to succinimide which sinks in CC14). The 
solution was filtered and the solvent removed by rotary evaporator. The 
liquid was distilled under reduced pressure to yield 10.6g of p- 
bromomethylacetophenone (63% yield), bp 99-100° (0.05 mmHg), NMR (CDCI3): 
<5 =7.2-7.8 (q,4H), 4.4 (s,2H), 2.2 (s,3H). 
p-Bromomethylphenylalyoxal [The proper name is 4-bromomethyl-a-oxo- 
benzeneacetaldehyde, — This compound was synthesized by oxidation of 
p-bromomethylacetophenone with selenous acid following a modified 
literature procedure (126). A solution of selenous acid (2.24 g; 0.017 
moles) and dioxane (15 ml) was heated at "55 °C for 15 minutes until all the 
solid had gone into solution. p-Bromomethylacetophenone (3.89 g? 0.018 
moles) was added in one lot and the reaction mixture, under a constant 
stream of argon gas, was slowly brought to reflux and held at 98-100°C for 
2 hours. The warm solution was decanted off the precipitated black 
selenium metal and concentrated on a rotary evaporator. Column 
chromatography was performed to isolate the desired reaction product. A 
glass column (inner diameter = 3.5 cm; length = 80 cm) was filled with 
silica gel (175 g). A total of ~2 liters of solvent starting with 20% 
ethylacetate in hexanes and ending with 100% ethylacetate was used for 
product elution. A Buchler Automatic Fraction collector was used to 
collect "20 ml fractions. The isolated products within each fraction were 
identified by thin layer chromatography (TLC eluting solution: 50% 
hexanes, 50% ethylacetate). The desired product, p- 
bromomethylphenylglyoxal eluting at 20% hexanes and 80% ethylacetate 
solution, was concentrated under reduced pressure and determined to be >95% 
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pure by nmr. (Column yield: 37%) mp. 101~103°C; NMR (acetone-dg): &-9.2 
(s,0.2H) , 6.9-7.6 (q,4H), 5.4 (s,0.6H), 4.2 (s,2H); NMR (D20): 5 =7.1-7.8 
(q,4H), 5.6 (s,lH), 4.3 (s,2H), 4.0 (H20)? Xmax=262nm, e262=~15'800 
M^cm”1. A sample was recrystalized twice from ethylacetate and determined 
to be the monohydrate by elemental analysis. Anal. (CgHgBrC^) C,H,Br. El 
mass spectrum, m/e (relative intensity): 197,199(M+-CHO, 100), 169,171 
(M+~COCHO,5), 147(M+-Br,10), 118(M+-Br-CHO, 100), 90 (M+-Br-OOCHO, 100). 
p-Fluoromethylacetophenone — p-Fluoromethylacetophenone was 
synthesized from p-bromomethylacetophenone using a fluorinated resin (127). 
The anion exchange resin (1 kg? Sigma, Amberlite IRA-900; Chloride) was 
first converted to the hydroxy-form by washing it with IN NaOH (3 liters) 
followed by warm distilled H20 (~10 liters) until the wash solution pH 
turned ~7.0. In a completely glass-free aparatus, the resin was then 
converted to the fluoride-form by washing it with 1 M hydrofluoric acid 
(2.5 liters) followed by washings with H20 (~15 liters) until washings 
reached near neutral pH. The resin was then washed with 95% EtOH (~1 
liter) and then with benzene C250 ml). The resin was dried overnight in a 
dessicator under vacuum, then rotovapped. A portion of this partially 
dried resin (250 g) was suspended in dry benzene (previously dried over 
sodium metal, distilled, and then stored over molecular seives) for 
additional dehydration which was performed by refluxing it for 24 hrs in a 
Soxhlet extractor containing molecule sieves. The benzene was then removed 
by vacuum and low heat. The fluorinated resin (64 g; 3.4 mequiv. F~/gram) 
was suspended in 375 ml of pentane. p-Bromomethylacetophenone (5.7 g; 
0.027 moles) was added and the vigorously mixed solution was slowly heated 
to reflux and left refluxing for ~2 days. The liquid was decanted off the 
resin and concentrated under reduced pressure to yield 0.35 g (9%) of 
product. Ether washings of the resin resulted in the collection of 0.5 g 
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(12%) of product. Methylene chloride washings (total of 400 ml) yielded 
2.4 g (59%) of desired product, NMR (CDCI3): 5 =7.2-8.0 (q,4H), 5.8 
(s,0.7H), 5.0 (s,0.7H), 2.5 (S,2.9H). The combined samples were distilled 
under reduced pressure to yield 1.8 g (overall yield 45%) of >95% pure p- 
fluoromethylacetophenone, bp 45°C (0J. mmHg), NMR (CDCI3): 5 =7.2 - 7.9 (q, 
4H), 5.8 (S,1H), 4.9 (s,lH), 2.5 (s,3H) Anal. (C9H9FO) C,H. 
p-Fluoromethylphenylalyoxal - (The proper name is 4-fluoromethyl- a - 
oxo-benzeneacetaldehyde). This compound was synthesized in the same manner 
as the bromo-analog. Thus, fluoromethylacetophenone (0.95 g; 0.0063 
moles), selenous acid (0.84 g; 0.0065 moles), and dioxane (5 ml) were 
reacted under argon gas for 2 hrs. The crude reaction product was then 
purified on a 55 gram silica gel column (inner diameter = 2.2 cm; length = 
50 cm). The desired product, p-fluoromethylphenylglyoxal-monohydrate, 
eluted with a 35% hexanes and 65% ethylacetate solution in 60% yield, mp. 
120-122°C, NMR (acetone-dg, poorly soluble): 5 =6.8-7.7 (q,4H), 5.3 
(s,0.7H), 5.0 (1.6,H), 4.5 (s,0.7H). X max=253, e253=~12'400 M”1cm”1. 
Anal. (C9H9F03) C,H. 
B. ENZYMATIC METHODS 
All pH measurements were determined with an Orion Research model 601A 
Digital Ionalyzer equipped with an Orion Research Semi-micro Combination pH 
Electrode. Enzymatic reactions were usually carried out in a 0.05 to 0.2M 
potassium phosphate buffer at a pH between 6.0 to 7.5. Ketoaldehyde and 
GSH concentrations ranged between 0.1 to 2.0 mM. Glyoxalase I [S- 
lactoylglutathione methylglyoxallyase (isomerizing) EC 4.4.1.5 (Sigma, 
Yeast, Grade X)] was commonly used at 1 to 3 units per ml of reaction 
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mixture where 1 unit is defined as the amount of enzyme which will convert 
1.0 umole of substrate to product per minute at pH 6.6 at 25 °C. Glyoxalase 
II [S-2-hydroxyacylglutathione hydrolase EC 3.1.2.6 (Sigma, Beef liver)] 
was used at 0.5 to 1.5 units/ml of reaction mixture where 1 unit is defined 
as the amount of enzyme that would hydrolyze 1.0 umole of S- 
lactoylglutatione per minute at pH 7.4 at 25°C. Reactions were followed by 
observing the decrease in absorbance of the halogenated 
methylphenylglyoxals at the noted wavelengths on a Beckman Model 35 
Spectrophotometer. Conditions of individual enzymatic experiments, 
including inhibition studies are reported in detail in the Results Section. 
Attempts were made to identify the products of the enzymatic reactions by 
both purification of the reaction mixture by passage through a Dowex-1 
formate column and by high pressure liquid chromatography. These samples, 
as well as actual enzymatic reaction mixtures were analyzed on a Bruker WM 
500-MHz NMR Spectrometer. Fluoride ion and bromide ion release were 
followed with an Orion Research Digital Ionalyzer (Model 601A) equipped 
with either an Orion Fluoride Electrode (Model 96-09) or an Orion Bromide 
Electrode (Model 94-35). 
Ketoaldehyde Stock Solution - Example of preparation: A stock 50 mM 
bromomethylphenylglyoxal-monohydrate solution would be prepared by 
dissolving 5.1 mg (0.021 mmoles) of compound in 420 ul of methanol or 
ethanol. Typical enzymatic reactions were run at a ketoaldehyde 
concentration of 0.2 mM. Therefore, 4 ul of stock solution would be added 
to a 1 ml aqueous reaction mixture. 
GSH Stock Solution - Because glutathione is easily oxidized, GSH 
solutions were kept cold and prepared fresh daily. A stock 50 mM GSH 
solution was prepared by dissolving 15.4 mg (0.05 mmoles) glutathione 
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(Sigma) in 1000 ul water. Typical enzymatic reactions had an equimolar to 
a ten times excess of GSH based on the ketoaldehyde concentration. 
1. Enzyme-Substrate Studies 
Spectrophotometric Studies - The halogenated methylphenylglyoxals were 
studied as substrates of the glyoxalase enzyme system. Reactants were 
mixed in a spectrophotometer cuvette (either 10 mm or 3 mm UV path length) 
in order to follow the course of the reaction spectrophotometrically. 
Thus, to a 3 mm path cuvette containing 974 ul of pH 6.0, 0.1 M potassium 
phosphate buffer, 8 ul of 46 mM stock substrate solution (final reaction 
concentration = 0J7 mM) and 16 ul of 51 mM stock solution (final reaction 
concentration = 0.8 mM) were added. The reaction was then followed 
spectrophotometrically with no enzyme present, with glyoxalase I (1 unit/ml 
of reaction mixture), or with glyoxalase I (1 unit/ral) and glyoxalase II 
(0.5 unit/ml of reaction mixture). Reactions containing p~ 
fluoromethylphenylglyoxal were followed at *=256nm. Reactions containing 
p-bromomethy lphenylglyoxal were followed at A=262nm. 
Hiah Resolution HME S.kll4ii£.£ - The reactions of p- 
bromomethylphenylglyoxal and GSH with the glyoxalase enzyme system were 
also followed by high resolution NMR. Reactions were carried out in an NMR 
tube containing buffer made with deuterated water and analyzed with a 500 
MHz NMR spectrometer. Bromomethylphenylglyoxal (3.2 mg, 0.013 mmoles) was 
disolved in 100 ul of deuterated methanol (CD3CD2OD). A 200 mM GSH 
solution was made by dissolving GSH (30.8 mg, 0.1 mmoles) in 500 ul of 
deuterated water. To 564 ul of a pD 6.1, 0.05 M potassium phosphate 
solution, 20 ul of the p-bromomethylphenylglyoxal solution (final 
concentration in reaction mixture = 4.4 mM) and 14 ul of the GSH solution 
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(final concentration in reaction mixture = 4.8 mM) was added and an NMR 
spectrum of the formation of the thiohemiacetal was recorded. Addition of 
2 ul of a glyoxalase I solution containing 5 units/ul of solution (final 
concentration of enzyme in reaction mixture =“17 units/ml) resulted in the 
conversion of the thiohemiacetal to its corresponding thioester. 
Isolation gf Products fox High Resolution NMR — Attempts were made to 
isolate the products of the reaction of p-bromomethylphenylglyoxal and GSH 
in the presence of glyoxalase I and II. Thus, to a pH 6.0, 0.1 M potassium 
phosphate buffer (30 ml), GSH (61.1 mg, 0.2 mmoles) was added. Because the 
pH fell to 4.7, 1 N NaOH was added to raise the pH to 6.0. Glyoxalase I 
(120 ul, 60 units), glyoxalase II (120 ul, 12 units), and a methanol 
solution of p-bromomethylphenylglyoxal (24.2 mgy 0.1 mmoles in 200 ul 
MeOH) was then added and the reaction mixture was reacted for 1 hr under an 
argon atmosphere. The reaction mixture was then loaded onto a Dowex-1 
formate column (outer diameter = 1.3 cm; length = 50 cm) at 3KC. The 
product was eluted off the column with a 0 to 6 M formic acid linear 
gradient (400 ml + 400 ml). Fractions of “5 ml were collected by an 
automatic fraction collector. The presence of a product in a fraction was 
identified by measuring the absorbance of each fraction on a Beckman DU 
Spectrophotometer (Model 2400) at X=266 nm. The fractions which contained 
product were combined and concentrated under reduced pressure. Before NMR 
analysis was performed, the sample containing product was washed numerous 
times with D20. 
High pressure liquid chromatography (HPLC) was used to further purify 
the major product found by Dowex-1 formate column chromatography. The 
concentrated solution was placed on a Alltech HPLC Column (Cat. #8250; Frit 
size: 2 u; inner diameter = 4.6 mm; length = 25 cm; packing material: 
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Partisil 10 ODS2, size 10 u) in 50 ul alliquots and eluted with distilled 
water. The major peak detected by a Gilson UV Spectrophotometer at *=266 nm 
was collected by numerous injections of the concentrated material from the 
Dowex-1 formate column onto the HPLC column. The combined samples were 
concentrated under reduced pressure, washed numerous times with deuterated 
water, and then analyzed by high resolution NMR. 
2. "Inverse" Substrate Studies 
Spectrophotometric Studies — p-Bromomethylphenylglyoxal was tested as 
an inverse substrate of glyoxalase I. Thus, 0.3 mM p- 
bromomethylphenylglyoxal-monohydrate was incubated with an equimolar 
amount of GSH at pH 7.5, 0.1 M potassium phosphate buffer for 3 to 6 hours 
under an argon atmosphere. The pH of this solution was then adjusted to a 
pH 7.2 by adding to it an equal volume of pH 7.0, 0JL M potassium phosphate 
buffer. Glyoxalase I (1 unit/ml of reaction mixture) was added to this 
solution. (Any thiohemiacetal of p-bromomethylphenylglyoxal and GSH which 
had inadvertently formed was converted to its corresponding thioester and 
would undergo no further reactions.) Then, a ten times molar excess of 
either GSH (334 mM) or ethanethiol (334 mM; EtSH) was added. Reactions 
were followed by measuring the change in absorbance at *=260nm. After 
observing any reaction for half an hour, an additional ten times excess of 
ethanethiol was added to the mixture already containing ethanethiol, 
followed by the addition of an excess of GSH. Reactions were continuously 
followed spectraphotometrically as noted above. 
Isolation of Products for High Resolution NMR - The product of the 
"inverse" substrate reaction of p-(glutathio-methyl)phenylglyoxal and 
excess GSH with glyoxalase I and II was isolated and identified by high 
I 
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resolution NMR. To a 7.5, QJ. M potassium phosphate buffer (30 ml), GSH 
(120.9 mg, 039 mmoles) and p-bromomethylphenylglyoxal-monohydrate (22.8 
mg, 0.09 mmoles in 200 ul of MeOH) was added and allowed to react at room 
temperature for ~2 hours. Glyoxalase I (60 units) and glyoxalase II (12 
units) was then added and allowed to react for ~1 hr. This reaction 
mixture was then pumped onto a Dowex-1 formate column (outer diameter = 13 
cm; length = 50 cm) at 3°C. A 0 to 6 M formic acid linear gradient (400 ml 
+ 400 ml) was used to elute the products off the column. Fractions of “5 
ml were collected by an automatic fraction collector. The presence of a 
product in a fraction was identified by measuring the absorbance of each 
fraction on a Beckman DU Spectrophotometer (Model 2400) at A =266 nm. The 
fractions that revealed the presence of a product were combined, 
concentrated under reduced pressure, and then washed numerous times with 
deuterated water. 
3. Enzyme Inhibition Studies 
An initial simple screening stud/ was first carried out to determine 
if p-bromomethylphenylglyoxal would inhibit glyoxalase I activity. The 
initial velocity of the enzymatic reaction of 0.12 mM 
bromomethylphenylglyoxal and 2 mM GSH was observed with 0.5 units 
glyoxalase I/ml of reaction mixture. With the addition of more 
bromomethylphenylglyoxal, a new initial velocity was observed. As a 
control, an identical procedure was carried out with 0J.2 mM phenylglyoxal. 
A more detailed and rigorous study of the irreversible inhibitory 
effect of p-bromomethylphenylglyoxal on glyoxalase I was performed by 
incubating p-bromomethylphenylglyoxal (at 0.02, 03, and 2.0 mM) with two 
equivalents of GSH in the presence of 25 units glyoxalase I/ml of reaction 
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mixture in a pH 5.5, 0.1 M acetate buffer. At various time points an 
aliquot from this inhibition reaction mixture was added to an assay 
solution containing 0.4 mM methylglyoxal, 2 mM GSH in a pH 6.6, 0.1 M 
potassium phosphate buffer. The calculated enzyme concentration in this 
assay mixture after the transfer was "0.1 units glyoxalase I/ml of 
solution. An initial velocity of the conversion of the thiohemiacetal of 
methy lglyoxal to its corresponding thioester was measured by following the 
change in absorbance at X =240nm. Control experiments included a run in 
which the "inhibitor reaction mixture" contained no p- 
bromomethylphenylglyoxal, but contained the proper amount of ethanol (the 
solvent p-bromomethylphenylglyoxal was dissolved in). A second type of 
control study, which contained no GSH in the inhibitor reaction mixture, 
was run at each inhibitor concentration. This would reveal non-enzymatic 
inhibition. A third type of "control" allowed the formation of the inverse 
substrate, p-(glutathiomethy Dphenylglyoxal. This involved the pre¬ 
incubation of p-bromomethylphenylglyoxal and GSH for 45 minutes in a pH 
7.5, 0.1 M potassium phosphate buffer. To this solution, glyoxalase I was 
added and inhibition was followed as above. 
4. Methods of Measuring Ion Release 
Fluoride Ion Release - Fluoride release was determined following 
procedures outlined in the fluoride electrode Instruction Manual (128). A 
glass free apparatus was used. A calibration curve was made by mixing 
commercial standard samples (Orion) of known fluoride ion concentration 
with an equal volume of potassium phosphate buffer. Fluoride release 
during the enzymatic reactions (2 mM GSH, 0.5 mM fluoride substrate, 
glyoxalase I, 3 units/ml reaction mixture, glyoxalase II, 0.6 units/ml 
reaction mixture in 1000 ul of pH 6.0, 0.1 M potassium phosphate buffer) 
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was followed continuously using the fluoride ion electrode. Side by side 
controls were run using fluoromethylglyoxal, a known fluoride eliminating 
compound (96). 
Bromide ion Release - Bromide ion release was followed using modified 
procedures outlined in the bromide electrode Instruction Manual (129). 
Because of the bromide electrode's marked sensitivity to free thiols in 
solution (i.e. GSH), it was necessary to eliminate any free thiols before a 
bromide ion determination was performed. This involved stopping the 
enzymatic reaction by adding an excess of N-ethylmaleimide (NEM) which is 
known to react with free GSH (130,131) and thus protected the electrode 
from poisoning by free sulfhydryls. Calibration curves were made by mixing 
commerical standard samples (Orion) of known bromide ion concentration with 
an equal volume of potassium phosphate buffer containing GSH (ImM) and NEM 
(5mM). Bromide release during enzymatic reactions, run at the usual 
compound concentrations (i.e. 2 mM GSH, 0.5 mM bromide substrate, 
glyoxalase I, 3 units/ml, glyoxalase II, 0.6 units/ml in pH 6.0, 0.1 M 
potassium phosphate buffer), was measured with the bromide electrode by 
taking alliquots from the reaction mixture then adding it to a solution 
containing a five times excess of NEM. Bromomethylglyoxal (132) was used 
as a control. Because one was limited by the time it took for each bromide 
ion determination, a further modification of the procedure allowed the 
rapid time course of the reaction to be followed. This was done by 
removing 500 ul of the reaction mixture at the desired time points and 
adding it to 5 ul of 30% nitric acid. This lowered the solution's pH to 
2.5, a level that inactivated both glyoxalase I and II. Bromide ion 
release was then measured with the electrode by taking this solution and 
adding it to an equal volume of a potassium phosphate buffer at pH 8.0, 
thus making the pH of the resulting solution 6.8. The GSH in solution was 
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then immediately "inactivated" by adding a five-times molar excess of NEM 
before a bromide reading was taken. Calibration curves for this type of 
experiment were generated by adding a buffer solution which had undergone 
identical modifications to the standard samples of known bromide ion 
concentration. Five types of bromide elimination studies were performed. 
Three experiments were controls in which bromide ion measurements were 
taken on bromomethylphenylglyoxal alone, bromomethylphenylglyoxal with GSH, 
and bromomethylphenylglyoxal with glyoxalase I. The two other experiments 
performed were with bromomethylphenylglyoxal and GSH in the presence of 
glyoxalase I and in the presence of glyoxalase I and II. 
C. TISSUE CULTURE METHODS 
Standard tissue culture experiments were run on P388 and L1210 mouse 
leukemia cell lines. The cells were maintained in suspension culture at 
37°C in a 5% CO2 humidified atmosphere. Three times per week, 105 cells/ml 
were passed in PRMI 1640 medium supplemented with 10% beef inactivated 
fetal calf serum (GIBCO), streptomycin (100 ug/ml), penicillin (100 
units/ml), and 1% glutamine (100 mM). Agents were added 24 hours after 
c 
seeding (10 cells/ml). Cell counts were taken every 24 hours for three 
days. Agents tested were run at approximately, 10“4, 10 ”5, and 10“6 M. 
The compounds used were of highest purity available. Standard solutions 
for this set of experiments were made by first dissolving the desired 
compounds in methanol to make a 50 mM solution. The appropriate volume was 
then added to 5 ml H2O to make a 10”^ M solution. The compounds tested 
were: methylacetophenone, p-bromomethylacetophenone, p- 
fluoromethylacetophenone, phenylglyoxal, p-bromophenylyglyoxal, p- 
bromomethylphenylglyoxal and p-fluoromethylphenylglyoxal. 
- 
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a BIOLOGICAL TEST METHODS 
The newly synthesized halogenated methylphenylglyoxals were evaluated 
for their anti-cancer activity against L1210 tumor bearing mice following 
previously described procedures (133). L1210 ascites cells were withdrawn 
from the peritoneal fluid of donor CDF^ mice bearing 7-day growths. The 
suspension was centrifuged for 2 minutes, the supernatant decanted, and a 
10 fold dilution with isotonic saline was made. The cell number was 
determined with a Coulter particle counter, and the cell population was 
adjusted to 106 cells/ml. Transplantation was then performed by injecting 
0.1 ml (containing approximately 105 cells) of this solution 
intraperitoneally into each animal. The test compounds were administered 
by intraperitoneal injection, beginning 24 hours after tumor implantation 
followed by once daily injections for a total of 6 consecutive days. The 
test compounds were injected as fine suspensions following homogenization 
in 2 to 3 drops of 20% aqueous Tween 80 and then made up to the proper 
volume with isotonic saline. All test compounds were administered 
intraperitoneally in a volume of 0.5 ml. Anti-cancer activity of the test 
compounds were carried out at various concentrations. 
Bromomethylphenylglyoxal was tested at 1, 2.5, 5, 10, 25 and 50 mg/kg. 
Fluoromethylphenylglyoxal was tested at 10 and 50 mg/kg. For any one 
experiment, the mice were distributed into groups of 5 of comparable 
weight. Throughout the experiment, the mice had unlimited access to Purina 
Laboratory Chow pellets and water. Control tumor-bearing animals were 
given injections of comparable volumes of the vehicle solution not 
containing any test compound. 
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RESULTS 
A. Synthesis of Halogens ted Methylphenylglyoxals 
Brcmo- and fluoromethylphenylglyoxal were successfully synthesized 
from p-methylacetophenone. Methylacetophenone was selectively brominated 
with N-bromosuccinimide to yield p-bromomethylacetophenone. This compound 
was either directly oxidized with selenous acid to p- 
bromomethylphenylglyoxal or fluorinated with an ion-exchange resin to yield 
p-fluoromethylacetophenone. The fluorinated compound was then oxidized 
with selenous acid to p-fluoromethylphenylglyoxal. Both compounds were 
positively identified by NMR analysis and elemental analysis. Hie bromo- 
compound was also identified by mass spectroscopy. For details of 
syntheses and analyses see the Materials and Methods section. 
B. Balomethylphenylglyoxals: A Si±)6trate of Glyoxalase I and II 
Bromo- and fluoromethylphenylglyoxal were found to be substrates of 
glyoxalase I and II. At enzymatic reaction conditions of 0.37 mM 
bromomethylphenylglyoxal and two equivalents of GSH at pH 6.0 one could 
follow the rate of the reaction spectrophotometrically by observing the 
decrease in absorbance at X =260 nm. Hie conversion of the thiohemiacetal 
( X max=262 nm; e262=~^4'30^ M-1cm“^) of bromomethylphenylglyoxal and GSH 
to its corresponding thioester ( Xmax=234; e 2g2=~3rl00 M“^cm-1) was enzyme 
dependent and could be accelerated by the presence of glyoxalase II. (See 
Table 1). This was most likely due to the regeneration of GSH which 
results in a higher concentration of the thiohemiacetal which is the 
substrate of glyoxalase I. At identical enzymatic reaction conditions the 
rate of the enzymatic conversion of the thiohemiacetal ( X max=252 nm) of 
fluoromethylphenylglyoxal and GSH to its corresponding thioester 
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Table 1: 
Glyoxalase I 
(Unit/ml) 
Glyoxalase II 
(Unit/ml) 
Velocity (oo/min) 
BrMe^G1 FMec(>G2 
1 - 0.81 0.44 
1 0.5 0.77 0.47 
1 1.5 1.00 
3 - 0.95 
3 1.5 1.13 
1 
BrMe4>G: Brcrronethylphenylglyoxal (0.37mM) 
2 
FMe4>G: Fluoranethylphenylglyoxal (0.3 3mM) 
(£256=”2,500 M^cm-1) appeared slower than that of the bromo-compound. At 
A=256 ran, the initial velocity of the glyoxalase I (1 unit/ml of reaction 
mixture) catalyzed conversion of fluoromethylphenylglyoxal to its thioester 
was 0.44 O.D./minute. In the presence of glyoxalase I (1 unit/ml) and 
glyoxalase II (0.5 unit/ml of reaction mixture) the velocity was only 
slightly higher at 0.47 O.D./minute. 
C. p-BronKxnetjhylphenylglyoxal as a Precursor of an "Inverse" Substrate 
It was noted that p-bromomethylphenylglyoxal and GSH underwent a time 
dependent change in absorbance at A = 262 ran when mixed in a 01 7.2 to 7.5 
potassium phosphate buffer. After about 80 minutes, no further significant 
drop in absorbance was noted. This suggested that at high pH, GSH was 
attacking bromomethylphenylglyoxal at the reactive brominated benzylic 
carbon forming glutathiomethylphenylglyoxal (XXTV) [\ This was 
first shown enzymatically by adding glyoxalase I to a previously incubated 
mixture of approximately equimolar bromomethylphenylglyoxal and GSH. The 
change in absorbance noted at A = 260 ran was about less than a third of 
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the expected change in absorbance of enzymatic reactions at lower pH. This 
revealed that much of the GSH was in a form which prevented the formation 
of the thiohemiacetal. It appeared that the GSH was covalently attached to 
the benzylic carbon. To test if p~glutathiomethylphenyiglyoxal could act 
as an "inverse" substrate of glyoxalase I, excess ethanethiol (EtSH) was 
added to the mixture to form the thiohemiacetal (XXVb). This activated the 
Ol hydrogen making it acidic and allowed for potential proton abstraction 
by the active site base via inverse chemistry . In the presence of 
glyoxalase I, no change in absorbance was noted. However, when excess GSH 
was added, a large change in absorbance was noted, consistent with a 
typical glyoxalase I catalyzed reaction forming the corresponding thioester 
( e262“~3'500 M”1cm“1). At roughly 0.11 mM glutathiomethylphenylglyoxal 
and 10 equivalents of GSH the initial velocity of the glyoxalase I (1 
unit/ml) catalyzed reaction was 0J.4 CUVmin. When excess GSH was added 
to the reaction mixture containing ethanethiol, there was a typical change 
in absorbance noted, however, the initial velocity of the conversion of the 
thiohemiacetal to the thioester was about half the rate noted above. This 
finding was consistent with the competition of GSH and EtSH to form the 
thiohemiacetal of glutathiomethylphenylglyoxal. In this case, GSH must 
form the thiohemiacetal for processing by glyoxalase I. (See Figure 3). 
Thus while p-bromomethylpherrylglyoxal forms glutathiomethylphenylglyoxal, 
it does not undergo "inverse" substrate processing by glyoxalase I. 
However, the glutathione substituted methylphenylglyoxal does undergo 
enzymatic processing in the presence of excess glutathione. As further 
proof of the above, the reaction product (XXYD of 
glutathiomethylphenylglyoxal, excess GSH, and glyoxalase I and II was 
isolated by Dowex-1 formate column chromatography (first of two peaks; 
eluting at 1M formic acid) and identified as the proper product by high 
resolution NMR (See Figure 4). 
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Figure 5: 
Glutathiomethylphenylglyoxal1 as a Substrate of Glyoxalase I2 
TIME (MIN) 
1Glutathionethylphenylglyoxal was formed by incubating brcmo- 
methylphenylglyoxal (0.29mM) and GSH (0.3mM) for greater than 
3 hours in a 0.1M potassium phosphate buffer at pH 7.5 under 
argon gas. 
2 After formation of the glutathicmethylphenylglyoxal, the 
solution was added to an equal volume of 0.1M potassium 
phosphate buffer at pH 7.0 (the final solution's pH = 7.2). 
Reactions were followed at X = 260nm by first adding glyoxalase 
I (1 Unit /ml reaction mixture) to react with any excess GSH, 
then by adding the proper amount of thiol. 
3AA = Change in Absorbance = Absorbance - Initial Absorbance. 
‘‘Control experiment containing approximately an identical 
concentration of phenylglyoxal in a 0.1M potassium phosphate 
buffer at pH 7.2, along with GSH (1.5mM) and Glyoxalase I 
(1 Unit/ml). 
5Reaction mixture with excess GSH (1.5mM) . 
6Reaction mixture initially with excess ethanethiol (EtSH) 
(1.5mM) , then with excess GSH (1.5mM) . 
7Reaction mixture with excess EtSH (1.5mM). 
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Figure 4: 
Formation of the "Inverse" Substrate and Identification 
of the Enzymatic Product by Vi - nmr 
Br-CH2- -C0CH0 + 1 eq. GSM 
xv 
pH 7.5 
gs-ch2- -C0CH0 + BR 
xxiv 
GLY I 
No Reaction 
xxvi 
a: 7.2(q,4H),b: 5.0(s,lH), c: 4.2(q,lH), d,e: 3.7-3.9(3H), 
f: 3.5 (s,2H) , g: 2.7(q,lH), g: 2.5(q,lH),h: 2.1(m/2H), 
i: 1.9-2.0(m,2H). 
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D. Fluoride Release ty Fluorcmetbylphenylglyoxal? 
Under typical enzymatic reaction conditions with glyoxalase I alone or 
with both enzymes present, absolutely no fluoride ion elimination was 
observed for fluoromethylphenylglyoxal. (However, as shown previously, 
this compound was determined to be a substrate for glyoxalase I). No 
fluoride ion release was noted at a pH range of 6.0 to 7.3 or after 
extended reaction times of greater than 60 hours. Thus, p- 
fluoromethylphenylglyoxal, while acting as a substrate of the glyoxalase 
enzyme system, does not eliminate fluoride ion. Nor does p- 
fluoromethylphenylglyoxal undergo attack by GSH at the benzyl ic carbon to 
form glutathiomethylphenylglyoxal. Control experiments studying fluoride 
ion release using fluoromethylglyoxal confirmed previously published 
results (96). Thus, at pH 6.0 and 7.3, total fluoride release was observed 
when fluoromethylglyoxal and GSH were incubated at standard reaction 
conditions with glyoxalase I only. When glyoxalase I and II were present a 
single burst of fluoride release was detected. The ratio of fluoride 
released to total fluoride was 0.35 which agrees with the previously 
published partitioning ratio of 0.32 for fluoromethylglyoxal - yeast 
glyoxalase enzyme system (96). 
E. Bromide Release by BraDanethylphenylglyoxal 
The bromide ion release experiments were fraught with many 
methodological problems, some which remain unresolved and therefore prevent 
quantification of results. The first problem of the bromide ion 
electrode's sensitivity to GSH was nicely overcome by quenching the 
reaction with N-ethylmaleimide before reading were taken. This procedure 
reproducibly eliminated the GSH from causing incorrect Br~ release 
measurements. The unresolved problem which prevented the quantification of 
data was the apparent instability of the tested compounds in the presence 
' 
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of the bromide electrode. Thus, when one of the bromide containing 
compounds was present with the bromide electrode, a reading could be 
obtained showing bromide release. A second measurement of the same sample 
would show further bromide release. However, what can be preliminarily 
reported is the finding the p-bromomethylphenylglyoxal affords a 
substantial amount of bromide ion released which is enzyme catalyzed (See 
Figure 5). The expected trends are seen. The glyoxalase I catalyzed 
reaction appears to be on a path which would lead to total Br~ elimination. 
The glyoxalase I and II catalyzed reaction exhibited a burst of bromide 
release, but then no further release is measured. And, at pH 6.0 and a two 
times excess of GSH, there is a slow non-enzymatic release of bromide due 
to "inverse" substrate formation. The important control studies 
demonstrated little to no sponteneous bromide ion release from 
bromomethylphenylglyoxal or from this compound in the presence of 
glyoxalase I. 
F. Isolation of Enzymatic Products for High Resolution M®. 
Many attempts were made to isolate the products of the enzymatic 
reaction of bromomethylphenylglyoxal and two equivalents of GSH at pH 6.0 
with glyoxalase I (2 units/ml) and glyoxalase II (0.4 units/ml). Most 
attempts at isolating the enzymatic products by Dowex-1 formate column 
separation and by HPLC were unsuccessful and resulted in NMR spectra of 
unsatisfactory quality. A product which had undergone bromide elimination 
could not be clearly identified. Definitive identification of enzymatic 
products such as p-bromomethylmandelic acid were unsuccessful due to the 
interference of a large water signal on NMR tracings. 
Subsequent work in our laboratory (135) has identified the product of 
p-fluoromethylphenylglyoxal and GSH in the presence of glyoxalase I and II 
as p-fluoromethylmandelic acid. 
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Figure 5: 
Bromomethylphenylglyoxal — Bromide Ion Elimination1 
time (min) 
’■Reactions were carried out in a 0.1M potassium phosphate 
buffer at pH 6.0 with braronethylphenylglyoxal at 0.4mM and 
other reactants at the concentrations noted below. Analyses 
were performed as described in the METHODS section. 
2GSH (0.8mM); Glyoxalase I (1 Unit/ml of reaction mixture). 
3GSH (0.8mM); Glyoxalase I (1 Unit/ml); Glyoxalase II (0.5 
Unit/ml) . 
4GSH (0.8mM); No enzymes present. 
5Glyoxalase I (1 Unit/ml); No GSH present. 
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G. Identification of Enzymatic Products by High Resolution KIR 
Identification of products by NMR by direct analysis of reaction 
mixtures of bromomethylphenylglyoxal and GSH in the presence of glyoxalase 
I yielded more definitive results. At equimolar substrate and GSH 
concentrations# the formation of the thiohemiacetal could be observed by 
following the C-l hydrogen [6.1 ppm (s, 1H)]. With the addition of GSH, 
this singlet decreased in intensity as new peaks formed, indicating the 
formation of the thiohemiacetal. In the newly formed thiohemiacetal the 
diastereotopic protons of the C-l hydrogen are clearly resolved. In 
agreement with the previously reported (76) chemical shifts of similar 
protons of the thiohemiacetal of phenylglyoxal and GSH, two singlets of 
equal intensity were observed at 6.45 and 6.48 ppm as seen in Figure 6. In 
Figure 6: 
6,10 
-C-C-SG 
OH 
(ppm) 
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the presence of glyoxalase I there is total disappearance of these protons 
of the thiohemiacetal, thus suggesting glyoxalase I processing of the 
thiohemiacetal of bromomethylphenylglyoxal and GSH to a thioester. The 
formation of a methyl-group after protonation of the bromide elimination 
product (XXI) was not detected by high resolution NMR. It was also 
impossible to detect accurately the decrease in the intensity of the bromo- 
methylene peak which would suggest bromide elimination. This was 
unachievable because the nmr signal of the brominated methyl-group of the 
starting material fortuitously fell at the same ppm of the H2O signal. 
However, if one attempted to ignore the large interference by the water 
peak, one could determine a slight decrease in the brominated methylene 
signal which might have revealed that bromide elimination had occurred to 
sane extent. 
H. Braaoaethylphenylglyoxal as a Glyoxalase Inhibitor 
The initial test screen for enzyme inhibition by the serial addition 
of bromomethylphenylglyoxal to a reaction containing greater than 15 
equivalents of GSH and 0*5 units of glyoxalase I/ml reaction mixture gave 
the first evidence that the compound was an inhibitor of glyoxalase I. 
That is, when compared to the initial velocity of the serial additions of 
phenylglyoxal to an identical reaction mixture, the addition of 
bromomethylphenylglyoxal caused a continuous decrease in the initial 
velocity with each subsequent additon (see Figure 7). 
I. Irreversible Inhibition of Glyoxalase I by p-Brcconethylphenylglyoxal 
At a given concentration of p-broraomethylphenylglyoxal, a time 
dependent inhibition of glyoxalase I was observed. The inhibition appeared 
to follow first order kinetics (see Figure 8). Glyoxalase I inactivation 
was also found to be dependent on the concentration of inhibitor (See 
\ 
Figure 7: 
Inhibition of Glyoxalase I by Serial Addition of 
Bromomethylphenylglyoxal (BrME^G) 
ADDITION (#) 
BRi^Ie4>G (Mfi) 
GSH (mM) 
GLY I (U/ML) 
1 2 
0,12 0.12 
2,0 
0.5 
3 ^ 
0,06 0.03 
INITIAL 
VELOCITY 
Control Experiment with Phenylglyoxal UG) 
ADDITION (#) 
<J>G (mM) 
GSH (MM) 
GLY I (U/ML) 
12 3 
0,12 0.12 0.06 
2,0 
0.5 
100% 100% 
80% 
INITIAL 
VELOCITY 

Figure 8: 
Bromomethylphenylglyoxal: Irreversible Inhibition of Glyoxalase I 
Plot of Time versus Activity Remaining1 
1 Activity Remaining was a measure of the initial velocity of the glyoxal¬ 
ase I catalyzed reaction of methylglyoxal (0.4mM) and GSH (2.0mM) as 
described in the METHODS section. 
2% Activity Remaining is defined as the change in absorbance per min. 
divided by the initial measurement of the change in absorbance per min. 
at time zero for each of the different reaction conditions. 
3Over Control: Inhibition solution contained glyoxalase I (25 units/ml of 
reaction mixture) and GSH (4mM) . No inhibitor, BrMel>G (brcmcmethylphenyl- 
glyoxal) added. 
[0.02mM] Control: Inhibitor solution contained glyoxalase I (25 U/rnl); 
BrMe^G (0.02mM). No GSH. 
5[0.2mM] Control: Inhibitor solution contained glyoxalase I (25 U/ml); 
BrMe4>G (0.2rrt4). No GSH. 
inhibition Study: BrMecfiG (0.02mM), GSH (0.04mM), Glyoxalase I (25 U/ml). 
7Inverse Substrate Formation: BrMe^G (0.2mM), GSH (0.4mM) were incubated 
for 45 mins, at pH 7.5 to form glutathicmethylphenylglyoxal. Then 
glyoxalase I (25 U/ml) was added and inhibition was followed with time. 
8[2.0mM] Control: Inhibitor solution contained glyoxalase I (25 U/ml); 
BrMe<j>G (2.0mM). No GSH. 
9Inhibition Study: BrMe^G (0.2mM); GSH (0.4mM); glyoxalase I (25 U/ml). 
inhibition Study: BrMe4>G (2.0mM); GSH (4.0mM); glyoxalase I (25 U/ml). 
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Figure 8). The graph of time of incubation versus the semi-log of the % 
activity remaining (See Figure 9) revealed the tjy2 (inactivation) to be 
approximately 9, 2.8, and 1.7 minutes at 2 x 10“^, 2 x 10“4, and 2 x 10~^ M 
respectively. The Kj, extrapolated from the graph of (1/inhibitor 
concentration) versus (l/k^nact^) was equal to 0.078 mM (See Figure 
10). The first control study which contained no inhibitor demonstrated 
>90% of enzyme activity present throughout the time period studied. The 
controls run at varying inhibitor concentrations, but without GSH present 
revealed slight enzyme inhibition, but at a much slower rate, and following 
non- first order kineticcs. The inhibition study in which 
glutathiomethylphenylglyoxal (the "inverse" substrate) was formed by 
incubating 0.2 mM p-bromomethylphenylglyoxal with 0.4 mM GSH at high pH 
resulted in enzyme inhibition, but at a lower level than when compared with 
0.2 mM p-bromomethylphenylglyoxal which had not undergone "inverse" 
substrate formation. The inhibition observed was probably due to unreacted 
p-bromomethylphenylglyoxal which had not undergone "inverse" substrate 
formation at high 0!. 
As expected, further work in our laboratory (135) has demonstrated 
that fluoromethylphenylglyoxal does not cause irreversible inhibition of 
glyoxalase I. 
J. Tissue Culture Experiments 
Bromo- and fluoromethylglyoxal were tested as growth inhibitors of 
L1210 and P388 cell lines in tissue culture as a preliminary test screen 
for the compound's anti-cancer activity. The results are summarized in 
Figure 11 which graphs the ratio of the cytotoxic effects on tumor growth 
of the test compounds to controls versus time. Both compounds at 10“4 M 
showed greater that 50% inhibition of growth of the L1210 cell line at 24 
hours when compared to controls. Growth was shown to be further inhibited 
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Figure 9: 
Bromomethylphenylglyoxal: Irreversible Inhibition of Glyoxause I 
PLOT OF TIME VERSUS THE SEMI-LOG OF ACTIVITY REMAINING 
ACTIVITY 
REMAINING 
(%) 
TIME OF INCUBATION (MIN) 
m 
(mM) 
i/m 
(mM 1) (min) 
a 
^inact 
(min ) 
l/<- , 
' inact 
(min) 
0.02 50 9.0 0.077 13.0 
0.2 5 2.8 0.248 4.0 
2.0 0.5 1.7 0.408 2.6 
a 
<inact 0.693/TT 
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Figure 10: 
Bromomethylphenylglyoxal: Irreversible Inhibition of Glyoxalase I 
PLOTaOF lAinact VERSUS l/III 
^lot of best line by linear regression. 

Figure 11: 57 
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nbromomethyu\cetophenone (10 4 
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TIME (HRS) TIME (HRS) 
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72 
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by 72 hours to levels of 60% for fluoromethylphenylglyoxal and "80% for 
bromomethylphenylglyoxal. Against the P388 cell line, 
fluoromethylphenylglyoxal at 10“4 M showed no more than a 40% growth 
inhibition. Bromomethylphenylglyoxal at 10”4 M resulted in ~70% cell 
growth inhibition at 72 hours. The experiments which tested cell growth 
inhibition of p-methylacetophenone, p-bromoacetophenone, and p- 
fluoromethylacetophenone resulted in no significant inhibition. 
Bromomethylacetophenone resulted in ~40% cell growth inhibition at 72 hours 
when compared to controls. This was most likely due to impurities present 
in the p-bromomethylacetophenone solution. 
K. Biological Evaluation in Timor-Bearing Mice 
Hie halogenated methylphenylglyoxals were further evaluated for anti¬ 
cancer activity against LI210 tumor bearing mice. Hie compounds were given 
on 6 consecutive days at the same dose beginning 24 hours after 
intraperitoneal tumor implantation. The results are summarized in Table 2. 
Fluoromethylphenylglyoxal, at a dose of 10 mg/kg and 50 mg/kg showed no 
significant antineoplastic activity in this system and showed no toxicity 
at the doses tested. However, bromomethylphenylglyoxal was very potent and 
showed extreme toxicity at 25 mg/kg and 50 mg/kg with all mice (tying within 
24 hours after the first dose was given. Lesser toxicity was seen at 
doses of 5 mg/kg and 10 mg/kg, with all mice surviving the 6 consecutive 
treatments, but then all (tying before the untreated controls C (T/C) % less 
than 100%]. There was no significant anti-cancer activity observed at 
doses of bromomethylphenylglyoxal at 1.0 mg/kg and 2.5 mg/kg. 

Table 2: 
Biological Test of Halogenated Methylphenylglyoxals 
in Tumor-Bearing Mice1 
DOSE (mg/kg) 
NO. OF 
INJ,2 
TUMOR EVALN,3 4 
(test/control) 
L1210 
(T/C) * 
BrME4>65 50 1 2.0/8.8 23 
25 1 2.0/8.8 23 
10 6 6.8/8.8 77 
5 6 8.4/8.8 95 
2.5 6 9.8/8.8 no 
1.0 6 9.2/8.8 105 
FTfeG6 50 6 8.8/8.8 100 
10 6 9.4/8.8 107 
■'‘Compounds were injected intraperitoneally as suspensions 
24 hours after a standard inoculum of 105 L1210 lymphoid 
leukemia cells were implanted in CDFi mice. Five mice 
were in each test group. 
2Number of injections given once daily at the same dosage 
level. 
3Mean survival time of animals in days. 
4(T/C)% is the ratio of the mean survival time of treated 
animals to control animals expressed as percent. In 
general, a decrease in survival time of treated animals 
as compared to control animals resulting in a (T/C)% of 
less then 100% reflected drug toxicity. 
5BrMe<J>G: Bromomethylphenylglyoxal 
6FMe<J>G: Fluoromethylphenylglyoxal 
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DISCUSSION 
Novel halogenated keto-aldehydes were successfully synthesized in high 
yield. The basis for their design was to synthesize a substrate for 
glyoxalase I that might, when activated by the enzyme, form a highly 
reactive compound that would be susceptible to Michael addition by a 
nucleophile at the active site. Such a strategy would create a covalently 
linked compound in the active site, thus inactivating the enzyme. This 
scheme, which proceeds via halogen elimination, provides further evidence 
that the glyoxalase I mechanism proceedes through a fast-shielded proton 
transfer and not by a hydride shift. The newly synthesized compounds were 
also tested as possible "inverse" substrates of glyoxalase I. 
Like other halogenated methylglyoxals described by Kozarich (99) which 
form "inverse" substrates of glyoxalase I, bromomethylpherrylglyoxal was 
found to react non-enzymatically with GSH at high pH forming p- 
glutathicmethylphenylglyoxal. This could be observed by the slow change in 
IN absorbance, as well as by the slow elimination of bromide ion detected 
by the bromide electrode. This type of reaction was not observed when 
fluoromethylphenylglyoxal was incubated under identical conditions with 
GSH. This might be expected because the fluoride ion is not as a 
sufficiently good leaving group when compared to the bromide ion. However, 
when the uniquely formed glutathiomethylphenylglyoxal was incubated with 
glyoxalase I and ethanethiol, which renders the former aldehydic proton 
acidic and thus potentially susceptible to proton abstraction by the active 
site base, no enzymatic reaction was observed. This is in marked contrast 
with glutathiomethylglyoxal which Kozarich & Chari (99) found to undergo 
inverse substrate processing. Because glutathiomethylphenylglyoxal was 
unreactive in the inverse reaction, this suggests, as we recently reported 
(134), that there is a constraint on the distance and geometry between the 
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glutathione moiety and the a -keto-aldehyde in the inverse reaction (See 
Figure 12). However, when glutathiomethylphenylglyoxal was incubated with 
Figure 12: 
excess GSH, glyoxalase I successfully converted it to its 
corresponding a-hydroxythioester which, in the presence of glyoxalase II, 
was hydrolyzed to the hydroxy acid. Hiis product was successfully isolated 
and identified by high resolution NMR. The processing of the thiohemiacetal 
of glutathiomethylphenylglyoxal and GSH by glyoxalase I provides an 
additional example of the requirement of glyoxalase I for GSH for binding 
and the enzyme's nonspecificity for the a-keto-aldehyde. In this case, 
a methylphenylglyoxal with a tripeptide side chain was successfully 
processed by glyoxalase I and II. This might indicate the ability of the 
glyoxalase system to process large macromolecules containing keto-aldehyde 
side chains. Such a proposition could be significant in yet to be 
discovered important intracellular substrates which might be key to the 
definitive physiological function of glyoxalase. 
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The findings that the thiohemiacetals of brorao- and fluoromethyl- 
phenylglyoxal and GSH are substrates of glyoxalase I are similar examples 
of the non-specific nature of glyoxalase for the a-keto-aldehyde and the 
highly specific nature of its binding to GSH. As can be expected, the 
thiohemiacetal of bromomethylphenylglyoxal and GSH was found, by high 
resolution NMR, to form two stereoisomers (76,77). Hiese two isomers are 
presumed to undergo equal processing by glyoxalase I (in the presence of 
enzyme, both disappear). Hie newly formed thioester was not successfully 
identified. Of equal disappointment was our inability to identify, by NMR, 
the product of the enzymatic elimination of bromide. The possibility, 
however, remains that our attempts to identify the protonated intermediate, 
XXI. were unsuccessful because the quinoid-like intermediate, XIX. diffused 
out of the active site and was immediately attacked by a nucleophile (e.g. 
GSH) forming XXII. No attempts were made to isolate this product. And, 
because of the presence of GSH in the reaction mixture, such a product 
could not be easily identified by direct analysis by NMR of reaction 
mixtures. 
Nevertheless, enzyme dependent bromide elimination was observed using 
the techniques of bromide ion electrode analysis. These experiments 
strongly indicated the mechanism of glyoxalase I proceeds through a fast- 
shielded proton transfer with an enediol intermediate. Of significance, 
the elimination of the halide generating the quinoid-like structure XIX. 
requires a disruption of the aromatic ring. This loss of resonance energy 
might be expected to constitute a formidable energy barrier to halide 
release. It appears that bromide ion is a sufficiently reactive leaving 
group to over-come this energy barrier. Fluoride ion electrode studies 
demonstrated no fluoride ion release. Therefore, it appears that fluoride 
ion is not a sufficiently reactive leaving group to overcome the energy 
barrier of disrupting the aromatic reasonance structure. Consequently, if 
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bromide ion elination could be successfully quantified, one might be able 
to measure partitioning ratios as Kozarich & Chari did with 
fluoromethylglyoxal (96). The existence of various products is supported 
by the tentative identification of the non-elimination product, p- 
bromomethylmandelic acid (XXIII) and the observation that bromide ion 
release is an enzyme dependent process. In the presence of glyoxalase I, 
the trend appears to be toward total bromide elimination due to the 
continuous re-entry of the thiohemiacetal and thioester product into the 
active site for further processing. While in the presence of glyoxalase I 
and II, there appears to be a trend toward no further bromide release after 
the final hydroxy-acid product is formed. 
Hie demonstration of an enzyme dependent bromide ion release supports 
the hypothesis that the quinoid-like intermediate, XIX. is formed at the 
active site. This has important implications. The quinoid-like 
intermediate formed by bromide elimination takes on a planar configuration. 
Thus, it might be inferred that the active pocket is sufficiently 
nonspecific to permit the formation of the planar quinoid-like 
intermediate. Of greater significance is that this compound is highly 
susceptible to Michael addition by a nucleophile at the active site. This 
would then cause the covalent modification of the enzyme and thus 
irreversibly inhibit it. Such a possibility would represent the first 
mechanism-based irreversible inhibitor of glyoxalase I. 
Initial experiments studying the inhibition of glyoxalase I by 
bromomethylphenylglyoxal provide strong evidence that the compound is 
acting as a mechanism-based, irreversible inhibitor of glyoxalase I. The 
studies showed that the novel new haloketoaldehyde fulfills the initial 
criteria (122) for identifying suicide inactivation. The experiments 
demonstrated the loss of enzyme activity was time dependent, following 
first-order kinetics. The rate of inactivation was found to be 
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proportional to the inhibitor concentration. Saturation kinetics are 
observed at high concentrations of inhibitor (135). Further experiments 
that would allow us to definitively state that bromomethylphenylglyoxal is 
an irreversible inhibitor include substrate protection studies, where the 
rate of inactivation is decreased as one increases the concentration of 
substrate (e.g. methylglyoxal). Other important studies include extensive 
dialysis and column separation to try and reactivate the enzyme. For 
further proof of the covalent modification of the enzyme, one could 
radioactively label the inactivator and show that the radioactivity becomes 
irreversibly associated with the protein. 
Hie control experiments of the enzyme inhibition studies indicated an 
alternative process by which enzyme inactivation could occur. This was 
demonstrated in experiments which contained bromomethylphenylglyoxal at 
various concentrations incubated with glyoxalase I without GSH present. 
This result suggests that a non-mechanism-based enzyme inactivation is 
operative in the absence of GSH. 
At low concentrations there was a slow inactivation of the enzyme 
probably due to random alkylation of the enzyme by bromomethylphenylglyoxal 
(See Fig. 13). While at a high concentration of inhibitor, this non- 
FlGURE 13: 
enzymatic inactivation appeared more rapid, the latter was later shown to 
represent no more than 50% inactivation after 2 hrs. (135). The above 
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observations raise an interesting dilemma. In the presence of GSH, which 
"carries" the ketoaldehyde to the active site, is the inactivation of the 
enzyme due to an active site nucleophile simply displacing the bromide and 
forming a covalent link (See Fig. 14)? Or is the compound truly processed 
Figure 14: 
i 
through the quinoid-like intermediate followed by Michael addition? The 
former mechanism, which is due to an intrinsically reactive a - 
halomethylene reacting with an active site nucleophile, would represent an 
■affinity label" inactivation and not the hypothesized mechanism-based 
inactivation. In support of the former was our inability to identify 
bromide elimination products which had not been covalently attached to the 
protein. However, there is also data that strongly supports the hypothesis 
that bromomethylphenylglyoxal is being processed through the highly 
reactive quinoid-like intermediate which then inactivates the enzyme. If 
enzymatic inactivation occurred by an active site nucleophile attacking the 
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reactive a -halomethylene, for every bromide ion released, one would 
expect the result of an inactive enzyme. Thus, for "affinity label" 
inactivation, there would be a very small, almost nonmeasureable amount of 
bromide ion released. This was certainly not observed. One observed a 
significant amount of bromide ion release that was enzyme dependent. On 
the other hand, this finding is possible if the inhibitor proceeds through 
the proposed quinoid-1 ike intermediate. In such a scheme it is possible to 
have bromide elimination without requiring enzyme inactivation. Further 
proof of the probability of mechanism-based enzyme inhibition over affinity 
label type of inhibition is seen in the bromide ion electrode studies. The 
control experiment containing just inhibitor and glyoxalase I (no added 
GSH) revealed that an immeasurably small amount of bromine was eliminated. 
This observation indicates that the enzyme inactivation that was seen when 
the inhibitor and glyoxalase I were incubated occurred by a very small 
number of alkylations. If it had occurred via numerous alkylations, than a 
measureable quantity of bromide ion should have been present. It also 
gives strong evidence that bromomethylphenylglyoxal is being processed via 
the proposed intermediate which allows for the observed enzyme dependent 
bromide elimination. This is the only explanation for the findings that 
indicate that for inactivation to occur, bromide ion must be eliminated, 
but bromide ion elimination does not necessarily need to cause enzymatic 
inactivation. 
Further proof is needed to definitively assign bromomethylphenyl¬ 
glyoxal as a mechanism based irreversible inactivator of glyoxalase I. 
Besides the studies mentioned earlier which are required to conclude that a 
compound is a suicide inhibitor, other useful studies could be designed. 
One could prepare a compound like BrCH2-C6H4-CH2CH0 which would 
undergo thiohemiacetal formation with GSH. The thiohemiacetal would be 
able to specifically bind to the active site. One could then compare the 

67 
rate of enzymatic inactivation by this type of compound, which could only 
cause enzyme inactivation by an "affinity label" type mechanism, versus 
enzyme inactivation by bromomethylphenylglyoxal, which causes enzyme 
inactivation via a mechanism-based process. Such an experiment could give 
further evidence toward solving the dilemma of mechanism-based inhibition 
versus affinity label inhibition. 
Hie studies of the halogenated methylphenylglyoxal's cytotoxic effect 
on tumor cells in tissue culture and their anti-cancer activity in tumor¬ 
bearing mice strongly support the finding that p-bromomethylphenylglyoxal 
is an inhibitor of glyoxalase I and can potentially act as a useful anti¬ 
neoplastic agent. As expected, bromomethylphenylglyoxal inhibited the 
growth of L1210 and P388 cell lines is tissue culture. As an inhibitor of 
glyoxalase I, the compound could cause the build-up of growth inhibiting 
substances in cells in tissue culture and thus dramatically decrease tumor 
cell growth. When p-fluoromethylphenylglyoxal was incubated with the P388 
and L1210 cell lines, some growth inhibition was noted. The findings that 
f 1 uoromethylphenylglyoxal inhibited tumor growth, while it was not an in 
vitro mechanism-based irreversible inhibitor of yeast glyoxalase I, can be 
explained by one of two mechanism. Because fluoromethylphenlyglyoxal was 
shown to be a substrate of glyoxalase I, it can act as a competitive 
inhibitor. As a competitive inhibitor, in vivo, it can cause an initial 
accumulation of growth inhibiting substances that result in tumor growth 
inhibition. Another possible explanation of this compound's growth 
inhibiting effect in vivo is that the mammalian glyoxalase I enzyme may 
differ from the yeast enzyme and in contrast to the yeast enzyme the 
mammalian enzyme may cause fluoride elimination and formation of the 
reactive quinoid-1 ike intermediate that inactivates the enzyme. 
In support of the discovery that bromo- and fluoromethylphenylglyoxal 
cause tumor growth inhibition in tissue culture by specifically interacting 
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with the glyoxalase enzyme system is the finding that their synthetic 
precursors, methylacetophenone, p-fluoromethylacetophenone, and p- 
bromomethylacetophenone result in little to no inhibition of tumor growth 
in tissue culture. 
Brano- and fluororaethylphenylglyoxal were also tested in L1210 tumor¬ 
bearing mice by the intraperitoneal injection of the compounds for six 
consecutive days. As expected, at the doses tested, 
fluoromethylphenylglyoxal showed no increased survival in the treated 
tumor-bearing mice. This is an agreement with the in vitro enzymatic 
studies which demonstrated that the fluoro- compound did not act as an 
irreversible inhibitor of glyoxalase I. However, bromomethylphenylglyoxal 
at 50 mg/kg and 25 mg/kg resulted in extreme toxicity. The L1210 tumor¬ 
bearing mice only survived through one dose of the compound. The mice 
treated with this compound at 10 mg/kg and 5 mg/kg survived the complete 
course of six treatments, but died before the non-treated controls. At 
lower doses, no significant increase in survival was noted. The extreme 
toxicity of bromomethylphenylglyoxal in tumor-bearing mice is in keeping 
with the potent effect of an irreversible, suicide inhibitor which 
completely inactivates an enzyme. In this case, the inhibition of 
glyoxalase I leads to the overwhelming accumulation of substances which 
inhibit cell growth and division and cause the death of the animal. Thus, 
the treatment schedule of therapy beginning 24 hours after tumor 
implantation followed by treatment for six consecutive days was not the 
optimum regimen for evaluating the anti-cancer effects of p- 
bromomethylphenylglyoxal. Perhaps a different evaluation program specified 
by the Drug Evaluation Branch of the National Cancer Institute will yield 
more definitive results. One such evaluation involves the treatment of 
tumor-bearing mice beginning 24 to 48 hours after tumor implantation 
followed by treatment intervals of every fourth day (133). Such an 

69 
evaluation program could optimize the anti-tumor effect and diminish the 
toxic effects of bromomethylphenylglyoxal. 
.the cancer cell is unable to arrest growth 
because it is unable to inactivate its glyoxal- 
ase, which destroys the ketone-aldehyde that 
keeps the cell at rest... 
-A. Szent-Gyorgyi (13) 
The design and synthesis of inhibitors of specific key metabolic 
enzymes has been an important new approach in the development of potential 
anti-cancer agents. p-Bromomethylphenylglyoxal appears to be the first 
mechanism-based, irreversible inhibitor of glyoxalase I. This compound may 
be a potential anti-neoplastic agent and may help to further elucidate the 
definitive function of the glyoxalase enzyme system. And if Szent- 
Gydrgyi's theory is one day proven wrong, something will be left afterward. 
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